<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01537029</url>
  </required_header>
  <id_info>
    <org_study_id>A11-3691</org_study_id>
    <nct_id>NCT01537029</nct_id>
  </id_info>
  <brief_title>Effect of Weight on the Population Pharmacokinetic Analysis of Doxorubicin and Cyclophosphamide</brief_title>
  <official_title>Effect of Weight on the Population Pharmacokinetic Analysis of Doxorubicin and Cyclophosphamide</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Texas Tech University Health Sciences Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Texas</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Texas Tech University Health Sciences Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the effect of weight on doxorubicin and cyclophosphamide plasma clearance in
      participants who are normal weight (body mass index [BMI] &lt; 25 kg/m2, overweight or class I
      obese (BMI 25-34.9 kg/m2), or class II-III obese (BMI â‰¥ 35 kg/m2). The hypothesis is that
      participants who weigh more will have higher doxorubicin and cyclophosphamide clearances than
      participants who weigh less. Restated, the area under the drug-concentration time profile,
      also known as the AUC, in participants will decrease as participant weight increases.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This single site study will be conducted at the UT Southwestern Simmons Cancer Center. This
      study is designed to measure drug concentrations in the blood of 18 female breast cancer
      patients who require doxorubicin (30 minute infusion) and cylcophosphamide (30 minute
      infusion) as part of standard medical care. Up to a total of 40 adult female participants
      will be consented for the study at the cancer center. Eighteen of these participants are
      needed to complete the study. The others will likely be screen failures. The participants
      will have no more than 100 ml of blood drawn via a peripheral intravenous catheter just prior
      to the doxorubicin infusion, and then at 0.5, 1, 1.5, 2, 3, 4, 5, 12-24, and 24-72 h after
      the beginning of the doxorubicin infusion. The 5 hour blood draw is optional. The intravenous
      catheter will be removed when the participant is discharged from the cancer center on day 1.
      The participant will be asked to return to the cancer center at 12-24 and 24-72 hours to have
      the final 2 blood draws conducted.

      The participants must be treated with Doxurubicin and Cyclophosphamide in order to
      participate in this pharmacokinetic analysis study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 2012</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clearance (Cl) for Doxorubicin and Cyclophosphamide</measure>
    <time_frame>0-48 hours</time_frame>
    <description>Cyclophosphamide analysis was not possible due to rapid drug degradation</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Doxorubicin and cyclophosphamide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>Dosed by the patient's treating physician according to local standard of care.</description>
    <arm_group_label>Doxorubicin and cyclophosphamide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>dosage form: IV, Dosage, frequency, and duration: According to local standard of care</description>
    <arm_group_label>Doxorubicin and cyclophosphamide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Females, age 18 years of age or older, of all racial and ethnic origins that are
             scheduled to receive the first cycle of a single intravenous dose of doxorubicin (30
             minute infusion) and cylcophosphamide (30 minute infusion) as part of standard medical
             care for breast cancer. English and/or Spanish speaking participants are eligible to
             participate.

        Exclusion Criteria:

          -  Pregnant or nursing or unwilling to use a reliable contraception method during the
             study. The effects of doxorubicin and cyclophosphamide on pregnancy are unknown. In
             addition, the metabolic changes that accompany pregnancy may alter the
             concentration-time profile of doxorubicin or cyclophosphamide, so that the pregnancy
             and post-partum state would be a confounding variable.

          -  Participants unwilling to comply with study procedures.

          -  CrCl &lt; 10 ml/min

          -  Participants requiring peritoneal or hemodialysis

          -  Serum bilirubin &gt; 1.19 mg/dL

          -  Receipt of the following drugs that: a) Alter doxorubicin concentrations:
             carbamazepine, cyclosporine, fosphenytoin, paclitaxel, phenytoin, sorafenib,
             valspodar, verapamil; b) Alter cyclophosphamide concentrations: cyclosporine,
             nevirapine, ondansetron; c) All other drugs will be reviewed during screening of the
             patient
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ronald G Hall, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Texas Tech University HSC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas Southwestern</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>February 16, 2012</study_first_submitted>
  <study_first_submitted_qc>February 21, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 22, 2012</study_first_posted>
  <results_first_submitted>July 24, 2018</results_first_submitted>
  <results_first_submitted_qc>July 24, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">August 22, 2018</results_first_posted>
  <last_update_submitted>July 24, 2018</last_update_submitted>
  <last_update_submitted_qc>July 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast cancer</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Obesity</keyword>
  <keyword>Doxorubicin</keyword>
  <keyword>Cyclophosphamide</keyword>
  <keyword>Weight</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Doxorubicin and Cyclophosphamide</title>
          <description>Doxorubicin: Dosed by the patient's treating physician according to local standard of care.
Cyclophosphamide: dosage form: IV, Dosage, frequency, and duration: According to local standard of care</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Doxorubicin and Cyclophosphamide</title>
          <description>Doxorubicin: Dosed by the patient's treating physician according to local standard of care.
Cyclophosphamide: dosage form: IV, Dosage, frequency, and duration: According to local standard of care</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Clearance (Cl) for Doxorubicin and Cyclophosphamide</title>
        <description>Cyclophosphamide analysis was not possible due to rapid drug degradation</description>
        <time_frame>0-48 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Doxorubicin and Cyclophosphamide</title>
            <description>Doxorubicin: Dosed by the patient's treating physician according to local standard of care.
Cyclophosphamide: dosage form: IV, Dosage, frequency, and duration: According to local standard of care</description>
          </group>
        </group_list>
        <measure>
          <title>Clearance (Cl) for Doxorubicin and Cyclophosphamide</title>
          <description>Cyclophosphamide analysis was not possible due to rapid drug degradation</description>
          <units>L/hr</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.85" lower_limit="0.84" upper_limit="4.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Pre-dose until last blood draw (24 to 48 hours was the last time point if participant completed all blood draws)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Doxorubicin and Cyclophosphamide</title>
          <description>Doxorubicin: Dosed by the patient's treating physician according to local standard of care.
Cyclophosphamide: dosage form: IV, Dosage, frequency, and duration: According to local standard of care</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Ronald Hall</name_or_title>
      <organization>TTUHSC</organization>
      <phone>2143589009</phone>
      <email>ronald.hall@ttuhsc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

